-
EP3715341
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3715341
| EP3715341 - HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 10.03.2023 Database last updated on 15.06.2024 | |
| Former | Request for examination was made Status updated on 28.08.2020 | ||
| Former | The international publication has been made Status updated on 01.06.2019 | Most recent event Tooltip | 13.11.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Nanjing Transthera Biosciences Co., Ltd. Floor 3, Building 9 Accelerator Phase 2 Biotech and Pharmaceutical Valley Jiangbei New Area Nanjing, Jiangsu 210032 / CN | [2020/40] | Inventor(s) | 01 /
WU, Frank Floor 3, Building 9 Accelerator Phase 2 Biotech and Pharmaceutical Valley Jiangbei New Area Nanjing, Jiangsu 210032 / CN | [2020/40] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [N/P] |
| Former [2020/40] | Grünecker Patent- und Rechtsanwälte PartG mbB Leopoldstraße 4 80802 München / DE | Application number, filing date | 18881966.8 | 21.11.2018 | [2020/40] | WO2018CN116606 | Priority number, date | CN201711163324 | 21.11.2017 Original published format: CN201711163324 | CN20181081619 | 29.01.2018 Original published format: CN201810081619 | CN201810854213 | 30.07.2018 Original published format: CN201810854213 | [2020/40] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019101086 | Date: | 31.05.2019 | Language: | ZH | [2019/22] | Type: | A1 Application with search report | No.: | EP3715341 | Date: | 30.09.2020 | Language: | EN | [2020/40] | Search report(s) | International search report - published on: | CN | 31.05.2019 | (Supplementary) European search report - dispatched on: | EP | 23.10.2020 | Classification | IPC: | C07D217/24, A61K31/33, A61K31/395, C07D401/00, C07D403/00, A61K31/4035, A61K31/404, A61K31/437, A61K31/4375, A61K31/472, A61P3/00, C07D209/08, C07D213/82, C07D471/04, C07D209/46, C07D209/48, C07D213/81, A61K31/44 | [2020/48] | CPC: |
A61P3/00 (EP,KR);
C07D209/08 (EP,KR,US);
C07D471/04 (EP,KR,US);
A61K31/4035 (EP);
A61K31/404 (KR);
A61K31/4045 (EP);
A61K31/437 (EP,KR);
A61K31/4375 (EP,KR);
A61K31/44 (EP);
A61K31/472 (EP,KR);
C07D209/46 (EP,KR,US);
C07D209/48 (EP,KR);
C07D213/81 (EP,KR);
C07D213/82 (EP,KR,US);
C07D217/24 (EP,KR,US);
Y02P20/55 (EP)
(-)
|
| Former IPC [2020/40] | C07D217/24, A61K31/33, A61K31/395, C07D401/00, C07D403/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/40] | Title | German: | HALO-ALLYLAMIN-SSAO/VAP-1-HEMMER UND DESSEN VERWENDUNG | [2020/40] | English: | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | [2020/40] | French: | INHIBITEUR DE SSAO/VAP-1 HALO-ALLYLAMINE ET SON UTILISATION | [2020/40] | Entry into regional phase | 18.06.2020 | Translation filed | 18.06.2020 | National basic fee paid | 18.06.2020 | Search fee paid | 18.06.2020 | Designation fee(s) paid | 18.06.2020 | Examination fee paid | Examination procedure | 06.06.2019 | Request for preliminary examination filed International Preliminary Examining Authority: CN | 18.06.2020 | Amendment by applicant (claims and/or description) | 18.06.2020 | Examination requested [2020/40] | 13.03.2023 | Despatch of a communication from the examining division (Time limit: M04) | 14.07.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 18.06.2020 | Renewal fee patent year 03 | 12.11.2021 | Renewal fee patent year 04 | 24.11.2022 | Renewal fee patent year 05 | 13.11.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XYI]WO2007120528 (JOLLA PHARMA [US], et al) [X] 1,2,14-16 * pages 24-28, compounds I-74, I-75; I-77 - I-81; I-92 - I-98; paragraph [0002]; claims 29-39 * [Y] 1-16 [I] 1-16; | [Y]WO2013163675 (PHARMAXIS LTD [AU]) [Y] 1-16* paragraphs [0025] , [ 200] - [0218]; claims 1-20 * |